Washington : The drug, Ranibizumab, has the potential to prevent blindness and visual impairment from age-related macular degeneration in non-Hispanic Caucasian patients, according to a computer-modeling study carried out by scientists at the Wilmer Eye Institute. Neil M. Bressler, M.D., of Wilmer Eye Institute, The Johns Hopkins University, Baltimore, and colleagues designed a modeling study using outcomes from three previous phase 3 ranibizumab trials. After gathering and analyzing data from the Beaver Dam Eye Study, as well as the US Census Bureau (2008), they predicted that 151,340 non-Hispanic Caucasian Americans would develop neovascular AMD in 2008.
Sleepiness impairs brain control over rich foods
Genetic factor controls obesity-induced inflammation